Although potential targets on SCLC therapy such as poly (ADP‐ribose) polymerase (PARP), enhancer of zeste homolog 2 (EZH2), or delta‐like canonical Notch ligand 3 (DLL3) have emerged, comprehensive studies are urgently needed (Saito et al., 2018). This evidence concerns the gene EZH2 and small cell lung carcinoma.